Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly

Registry ID

EUCTR2015-005184-16

Source registry

EUCTR

Phase

PHASE2

Sponsor

Sanofi Pasteur SA

Last update

2026-08-16

Conditions

• Poliomyelitis

Summary

- To describe in each group the immunogenicity of IMOVAX Polio administered intradermally or intramuscularly, one month after the booster dose given at 15-18 months of age in toddlers previously primed with three doses of IMOVAX Polio vaccine during the IPV25 study

Related clinical trials

• Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama
• Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine
• Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations
• Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh
• Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
• A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

View on source registry